moxifloxacin has been researched along with Burkholderia pseudomallei Infection in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Engler, C; Harris, P; Norton, R | 1 |
| Brooks, TJ; Lever, MS; Nelson, M; Piercy, T; Simpson, AJ; Steward, J | 1 |
2 other study(ies) available for moxifloxacin and Burkholderia pseudomallei Infection
| Article | Year |
|---|---|
Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Burkholderia pseudomallei; Carbapenems; Doripenem; Ertapenem; Fluoroquinolones; Humans; Melioidosis; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Quinolines; Tigecycline | 2011 |
Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Dexamethasone; Drug Administration Schedule; Female; Fluoroquinolones; Gatifloxacin; Glucocorticoids; Melioidosis; Mice; Mice, Inbred BALB C; Moxifloxacin; Quinolines | 2005 |